Supplementary Table 1.

Details of clinical samples used in the capture-fusion phenotyping assay

Patient no.	Therapy	Outcome	SOF/RBV sensitivity	Age, y	Sex	Cirrhosis	Previous IFN treatment	Baseline viral load, IU/mL	NS5A RAS, baseline
1	SOF/DAC/RBV	SVR	Sensitive	59	M	Decompensated	Yes	2,178,912	—
2	SOF/VEL	SVR	Sensitive	32	F	Compensated	No	5,992,729	—
3	Ombitasvir/paritaprevir/ritonavir+SOF	SVR	Sensitive	61	F	Non-cirrhotic	Yes	2,301,777	—
4	SOF/DAC	SVR	Sensitive	59	F	Non-cirrhotic	No	2,663,854	—
5	SOF/LDV/RBV	Relapse	Sensitive	47	M	Decompensated	No	2,321,679	—
6	SOF/DAC/RBV	Relapse	Sensitive	49	M	Decompensated	Yes	1,913,455	—
7	SOF/LDV/RBV	Relapse	Sensitive	52	M	Decompensated	Yes	808,776	—
8	SOF/LDV	Relapse	Sensitive	49	M	Decompensated	No	3,100,000	—
9	SOF/DAC/RBV	Relapse	Insensitive	48	M	Decompensated	No	1,585,601	Y93H
10	SOF/LDV/RBV	Relapse	Insensitive	54	M	Decompensated	No	255,934	—
11	SOF/LDV/RBV	Relapse	Insensitive	56	M	Non-cirrhotic (transplant graft)	Yes	2,362,045	—
12	SOF/DAC/RBV	Relapse	Insensitive	58	M	Decompensated	Yes	902,000	—
13	SOF/LDV/RBV	Relapse	Insensitive	43	M	Decompensated	No	5,670,819	NA
14	SOF/LDV/RBV	Relapse	Insensitive	50	M	Decompensated	Yes	570,000	Y93H

NOTE. Details of the samples used in the capture fusion assay (Figure 1 and Table 1). Data include treatment, clinical outcome, age, sex, disease status, and baseline viral load.

F, female; LDV, ledipasvir; M, male.